文献速递疼痛医学神经外科与老年麻醉

5-羟色胺-去甲肾上腺素再摄取抑制剂预防偏头痛和前庭性偏头痛:系统综述与荟萃分析

Serotonin-norepinephrine reuptake inhibitors for the prevention of migraine and vestibular migraine: a systematic review and meta-analysis.
PubMed 文献 · Reg Anesth Pain Med · 2020-03-23

该系统综述与荟萃分析纳入6项随机对照试验共418例患者,评估SNRIs预防偏头痛和前庭性偏头痛的疗效与耐受性。结果显示SNRIs较安慰剂减少偏头痛天数,与其他活性药物疗效相当;在前庭性偏头痛中文拉法辛降低眩晕严重程度评分和DHI情绪域评分优于其他活性药物;SNRIs与安慰剂及活性药物在因任何原因或副作用退出率上无显著差异。

要点

  • SNRIs较安慰剂减少偏头痛天数,与其他活性药物疗效相当。
  • 前庭性偏头痛中文拉法辛降低VSS和DHI情绪域评分优于其他活性药物。
  • SNRIs与安慰剂及活性药物的退出率无显著差异,临床安全有效。

核心结论

  • SNRIs用于偏头痛和前庭性偏头痛预防临床安全有效,优于安慰剂,不劣于其他活性药物。
  • SNRIs可能是伴有精神疾病的前庭性偏头痛患者的优选。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Web of Science和Cochrane Library数据库。
  • 纳入6项随机对照试验,共418例患者。

主要发现

  • 接受SNRIs的患者偏头痛天数少于安慰剂组(标准化均数差-0.38,95%CI -0.76至-0.01,p=0.04)。
  • SNRIs与其他活性药物的效应相当。
  • 前庭性偏头痛患者中,文拉法辛在降低VSS上显著优于其他活性药物(加权均数差-1.45,95%CI -2.11至-0.78,p<0.0001)。
  • 文拉法辛在降低DHI情绪域评分上显著优于其他活性药物(均数差-2.64,95%CI -4.97至-0.31,p=0.03)。
  • SNRIs与活性药物之间、SNRIs与安慰剂之间,因任何原因或副作用退出率无显著差异。

临床怎么用

  • SNRIs可作为偏头痛预防的选项,疗效不劣于其他活性药物且安全。
  • 前庭性偏头痛患者可考虑文拉法辛,尤其伴有精神疾病时。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The role of serotonin-norepinephrine reuptake inhibitors (SNRIs) in migraine prophylaxis has not been completely established. Current treatments for vestibular migraine (VM) are based on scarce evidence. We aimed to perform an updated review focusing on the efficacy and tolerability of SNRIs for migraine and VM prevention. METHODS: We searched the PubMed, Web of Science, and Cochrane Library databases for relevant studies. The primary outcome was migraine frequency. In the case of VM, the Dizziness Handicap Inventory (DHI) scores and Vertigo Severity Scores (VSSs) were extracted. RESULTS: Six randomized controlled trials involving 418 patients were analyzed. Patients receiving SNRIs had fewer migraine days than those receiving a placebo (standardized mean difference -0.38, 95% CI -0.76 to -0.01, p=0.04). The effects of SNRIs and other active drugs were comparable. In patients with VM, venlafaxine had a significant advantage over other active drugs in decreasing the VSS (weighted mean difference (MD) -1.45, 95% CI -2.11 to -0.78, p<0.0001) and the emotional domain score of the DHI (MD -2.64, 95% CI -4.97 to -0.31, p=0.03). We found no significant difference in the rate of withdrawals due to any reason or withdrawals due to side effects between SNRIs and active drugs and between SNRIs and a placebo. CONCLUSIONS: SNRIs were clinically safe and effective for migraine and VM prophylaxis, were better than a placebo, and not inferior to other active drugs. SNRIs may be a preferable choice for patients with VM with psychiatric disorders.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Wang F, Wang J, Cao Y, et al. Serotonin-norepinephrine reuptake inhibitors for the prevention of migraine and vestibular migraine: a systematic review and meta-analysis. Reg Anesth Pain Med. 2020. PMID: 32205412. doi:10.1136/rapm-2019-101207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。